Gene Expression of BRCA1, RRM1, and RRM2 in Lung Cancer Treatment
Author Information
Author(s): Boukovinas Ioannis, Papadaki Chara, Mendez Pedro, Taron Miquel, Mavroudis Dimitris, Koutsopoulos Anastasios, Sanchez-Ronco Maria, Sanchez Jose Javier, Trypaki Maria, Staphopoulos Eustathios, Georgoulias Vassilis, Rosell Rafael
Primary Institution: Theagenion Cancer Hospital of Thessaloniki, Greece
Hypothesis
The study investigates the effect of BRCA1, RRM1, and RRM2 mRNA expression on the clinical response to gemcitabine plus docetaxel in non-small-cell lung cancer patients.
Conclusion
The mRNA expression of BRCA1, RRM1, and RRM2 can help select non-small-cell lung cancer patients for personalized chemotherapy.
Supporting Evidence
- Patients with high BRCA1 expression had a higher probability of response to treatment.
- Low RRM2 expression was associated with better treatment outcomes.
- Patients were classified into risk groups based on gene expression levels.
Takeaway
Doctors can use the levels of certain genes in lung cancer patients to decide the best treatment, which might help them get better results.
Methodology
The study analyzed tumor samples from 102 chemotherapy-naïve advanced NSCLC patients treated with gemcitabine plus docetaxel, assessing mRNA levels via quantitative PCR.
Potential Biases
Potential biases may arise from the retrospective nature of the study and selection of patients.
Limitations
The study is retrospective and may not account for all variables affecting treatment response.
Participant Demographics
The study included 90% male and 10% female patients, with a median age of 60 years.
Statistical Information
P-Value
p=0.01 for BRCA1, p<0.0001 for RRM2
Confidence Interval
95% CI for BRCA1: 1.02–1.16; for RRM2: 0.91–0.97
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website